Nevertheless, several studies have shown that, even among patients with the same TNM stage [ 4 ], there may be significant variation in their clinical outcomes despite receiving the same treatment, owing to the genetic and epigenetic heterogeneity of cancer [ 5 , 6 ].
← all excerpts
Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.
1
—
—